Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01881204 · ClinicalTrials.gov registry record · NA
Hesperidin and Bone Health in Postmenopausal Women
A NA study, sponsored by Purdue University.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT01881204 is a NA study that has completed, run by Purdue University. The registered enrollment target is 12 participants.
The verdict
NCT01881204, a NA study, has completed, sponsored by Purdue University.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary objective of this clinical trial is to test hesperidin with and without CALCILOCK® for bone resorption suppressing effect in postmenopausal women. The secondary objective is the comparison between 41Ca technology and classical biomarker to evaluate bone resorption.
Interventions
- DIETARY_SUPPLEMENT Control
- DIETARY_SUPPLEMENT Hesperidin and Calcilock
- DIETARY_SUPPLEMENT Hesperidin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01881204
The ClinicalTrials.gov registry entry for NCT01881204 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue University, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Control is the first listed.
NCT01881204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01881204 about?
NCT01881204 is a clinical study titled "Hesperidin and Bone Health in Postmenopausal Women". The primary objective of this clinical trial is to test hesperidin with and without CALCILOCK® for bone resorption suppressing effect in postmenopausal women. The secondary objective is the comparison between 41Ca technology and classical biomarker to evaluate bone resorption.
What is the current status of trial NCT01881204?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2011-04. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01881204?
The interventions under investigation include: Control (DIETARY_SUPPLEMENT), Hesperidin and Calcilock (DIETARY_SUPPLEMENT), Hesperidin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01881204?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.